NTRK1 and metabolic syndrome: Chromium has a positive effect on blood glucose control by improving insulin signaling through the activation of the tyrosine kinase receptor and by stimulating the translocation of the protein glucose transporter 4 in adipocytes, whereas its supplementation has been demonstrated to prevent atherogenic dyslipidemia through a myriad of mechanisms that remain unclear (e.g., enhanced β-oxidation, cholesterol synthesis inhibition, expression of peroxisome proliferator-activated receptors) [48].